期刊文献+

噻唑-吡唑啉衍生物作为EGFR抑制剂的3D-QSAR和分子对接模型研究 被引量:1

3D-QSAR and Molecular Docking Model Study of Thiazole-pyrazoline Derivatives as EGFR Inhibitors
原文传递
导出
摘要 目的建立EGFR抑制剂结构和活性之间的关系模型,基于对分子活性产生影响的重要结构性因素的信息,设计新的抑制剂分子并预测其活性,为抑制剂分子的设计提供依据。方法使用Discovery Studio 2019软件进行3D-QSAR的研究以及偏最小二乘的计算;利用Autodock进行分子对接;使用LigPlot研究二维相互作用。结果模型具有较高的q^(2)(0.521),和r^(2)(r^(2)_(training)=0.993,r^(2)_(test)=0.916,r^(2)_(blind)=0.940),表明模型具有较高的预测能力和拟合能力。结论预测结果表明,新设计的化合物活性较高,为EGFR抑制剂分子的设计提供了参考。 OBJECTIVE To establish a model of the relationship between the structure and activity of EGFR inhibitors,and to design new inhibitor molecules and predict their activity based on the information obtained on important structural factors affecting activity,so as to provide a basis for the design of inhibitor molecules.METHODS Discovery Studio 2019 software was used for 3D-QSAR research and partial least squares calculation.Autodock was used for molecular docking.Study two-dimensional interactions by using LigPlot.RESULTS The model had a high q^(2)(0.521),and r^(2)(r^(2)_(training)=0.993,r^(2)_(test)=0.916,r^(2)_(blind)=0.940),indicated that the model had high predictive ability and fitting ability.CONCLUSION The prediction results show that the newly designed compounds have higher activity,providing reference for the design of EGFR inhibitor molecules.
作者 秦悦 叶春林 QIN Yue;YE Chunlin(College of Biological and Chemical Engineering,Zhejiang University of Science and Technology,Zhejiang Provincial Key Laboratory of Chemistry and Bioprocessing Technology for Agricultural Products,Hangzhou 310023,China)
出处 《中国现代应用药学》 CAS CSCD 北大核心 2023年第21期2984-2989,共6页 Chinese Journal of Modern Applied Pharmacy
基金 浙江省自然科学基金项目(LY17C020003)。
关键词 抑制剂 模拟筛选 聚类分析 分子对接 inhibitor simulation screening cluster analysis molecular docking
  • 相关文献

参考文献3

二级参考文献40

  • 1吴一龙.肺癌分子靶向治疗的个体化[J].循证医学,2004,4(2):67-68. 被引量:9
  • 2Krause,DS,Van,Etten,RA,黄艳.癌症治疗的靶点——酪氨酸激酶[J].中国处方药,2005(10):33-36. 被引量:45
  • 3Zhou H, Kim YS, Peletier A, et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR and HER2-overexpessing breast cancer cell line proliferation, radiosensitization, and resistance [ J ]. Int J Radiat Oncol Biol Phys ,2004,58(2):344- 352.
  • 4Smaill JB,Hollis HD,Zhou H, et al. Tyrosine kinase inhibitors. 18.6-substituted 4-anilinoquinazolines and 4-anilinopyrido [3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor[J]. J Med Chem ,2001,44(3) :429 - 440.
  • 5David WF, Alexander JB, William AD, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor[J]. Proc Natl Acad Sci USA,1998,95(9) : 12022 - 12027.
  • 6Tsou HR, Mamuya N, Johnson BD, et al. 6-substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity[J]. J Med Chem .2001.44(17) :2719-2734
  • 7Liechti C,Sequin U, Bold G, et al. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor [ J ]. Eur J Med Chem ,2004,39( 1 ) : 11 - 26.
  • 8Dancey J. Epidermal growth factor receptor inhibitors in clinical development[J]. Int J Radiat Oncol Biol Phys ,2004,58(3) : 1003 -1007.
  • 9Michael AG, Bock C, Ferguson LR. Evidence for epidermal growth factor receptorenhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033 [J].Anticancer Drugs ,2001,12(7) :683 - 690.
  • 10David WF, James MNe, Veronika S, et al. Biochemical and antiproliferative properties of 4-[Ar(alk) ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor[ J ]. Biol Pharmacol, 1997,54( 8 ) :877 - 887.

共引文献54

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部